Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo.
Active targeting
Exosome mimetics
Prostate cancer
Prostate-specific membrane antigen
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 02 2021
10 02 2021
Historique:
received:
16
06
2020
revised:
27
11
2020
accepted:
11
12
2020
pubmed:
18
12
2020
medline:
8
7
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
The present work describes the engineering of anti-PSMA peptide-decorated exosome mimetics (EMs) targeting advanced prostate cancer (PC). The targeted EMs were produced from anti-PSMA peptide, WQPDTAHHWATL, expressing U937 monoblastic cells, followed by successive extrusion cycles. The engineered EMs were nanosized, produced at a high yield, and displayed the anti-PSMA peptide, exosomal markers and monocytes proteins on their surface. As anticipated, PSMA-EMs showed increased cellular internalization in PSMA positive PC cell lines (LNCaP and C4-2B), compared to unmodified EMs. Most importantly, higher tumour targeting was observed in solid C4-2B tumours, following intravenous administration, confirming their targeting ability in vivo. Overall, our study indicates that the engineered anti-PSMA peptide-targeted EMs can be a promising drug delivery system for advanced PC.
Identifiants
pubmed: 33333118
pii: S0168-3659(20)30741-0
doi: 10.1016/j.jconrel.2020.12.017
pii:
doi:
Substances chimiques
Antigens, Surface
0
Glutamate Carboxypeptidase II
EC 3.4.17.21
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-110Subventions
Organisme : Prostate Cancer UK
ID : CDF12-002
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.